N- And O-Glycosylation Analysis Of Human C1-Inhibitor Reveals Extensive Mucin-Type O-Glycosylation
View/ Open
Date
2018Author
Stavenhagen, Kathrin
Kayili, H. Mehmet
Holst, Stephanie
Koeleman, Carolien A. M.
Engel, Ruchira
Wouters, Diana
Zeerleder, Sacha
Salih, Bekir
Wuhrer, Manfred
xmlui.mirage2.itemSummaryView.MetaData
Show full item recordAbstract
Human C1-inhibitor (C1-Inh) is a serine protease inhibitor and the major regulator of the contact activation pathway as well as the classical and lectin complement pathways. It is known to be a highly glycosylated plasma glycoprotein. However, both the structural features and biological role of C1-Inh glycosylation are largely unknown. Here, we performed for the first time an in-depth site-specific N- and O-glycosylation analysis of C1-Inh combining various mass spectrometric approaches, including C18-porous graphitized carbon (PGC)-LC-ESI-QTOF-MS/MS applying stepping-energy collision-induced dissociation (CID) and electron-transfer dissociation (ETD). Various proteases were applied, partly in combination with PNGase F and exoglycosidase treatment, in order to analyze the (glyco)peptides. The analysis revealed an extensively O-glycosylated N-terminal region. Five novel and five known O-glycosylation sites were identified, carrying mainly core1-type O-glycans. In addition, we detected a heavily O-glycosylated portion spanning from Thr82-Ser121 with up to 16 O-glycans attached. Likewise, all known six N-glycosylation sites were covered and confirmed by this site-specific glycosylation analysis. The glycoforms were in accordance with results on released N-glycans by MALDI-TOF/TOF-MS/MS. The comprehensive characterization of C1-Inh glycosylation described in this study will form the basis for further functional studies on the role of these glycan modifications.
URI
https://doi.org/10.1074/mcp.RA117.000240https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986245/
http://hdl.handle.net/11655/19637